Optimizing flow cytometry quantitation of rare-cell populations and its application in immunotherapy
In association with Eurofins Viracor BioPharma Services
Flow cytometry is capable of high-speed detection, quantitation and multi-parameter phenotyping of individual cells. Consequently, the combined rare event detection and characterization abilities of this technology on heterogeneous samples have made it the method of choice for a variety of research and clinical development applications. However, several important considerations need to be addressed prior to use in these applications. This webinar will discuss these considerations to help users ensure they have optimal flow cytometry assays for rare-cell event detection.
What will you learn?
- Do you have the correct parameters and gating strategies to identify your population of interest?
- How do you generate high precision and signal-to-noise for your rare-cell population of interest to ensure you have confidence in its detection?
- How can we use statistics to help us with identifying these rare-cell populations?
- How can rare-event detection capabilities of flow cytometry be applied to the clinical development of new immunotherapies (i.e., CAR T-cells)?
Who may this interest?
- Clinical development scientists
- Project/program leads
- Investigators studying cell and gene therapy
Speaker
Brian T Maybruck, PhD (MO, USA)
Senior Scientist-Immunology
Viracor-Eurofins
Brian has 18 years of bench molecular and immunology research experience and has extensive expertise in cell-based de novo protein detection method development (e.g., flow cytometry), validation, and implementation for the development of assays for testing associated with human and mouse tissues for in vitro, ex vivo, and/or in vivo analyses.